Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma

Rong Wu1, Tom C. Hu1, Alnawaz Rehemtulla2,4, Eric R. Fearon1,3,4, and Kathleen R. Cho1,3,4

Abstract

Purpose: Genetically engineered mouse (GEM) models of ovarian cancer that closely recapitulate their human tumor counterparts may be invaluable tools for preclinical testing of novel therapeutics. We studied murine ovarian endometrioid adenocarcinomas (OEA) arising from conditional dysregulation of canonical WNT and PI3K/AKT/mTOR pathway signaling to investigate their response to conventional chemotherapeutic drugs and mTOR or AKT inhibitors.

Experimental Design: OEAs were induced by injection of adenovirus expressing Cre recombinase (AdCre) into the ovarian bursae of Apcflax/flox;Ptenflax/flox mice. Tumor-bearing mice or murine OEA-derived cell lines were treated with cisplatin and paclitaxel, mTOR inhibitor rapamycin, or AKT inhibitors API-2 or perifosine. Treatment effects were monitored in vivo by tumor volume and bioluminescence imaging, in vitro by WST-1 proliferation assays, and in OEA tissues and cells by immunoblotting and immunostaining for levels and phosphorylation status of PI3K/AKT/mTOR signaling pathway components.

Results: Murine OEAs developed within 3 weeks of AdCre injection and were not preceded by endometriosis. OEAs responded to cisplatin + paclitaxel, rapamycin, and AKT inhibitors in vivo. In vitro studies showed that response to mTOR and AKT inhibitors, but not conventional cytotoxic drugs, was dependent on the status of PI3K/AKT/mTOR signaling. AKT inhibition in APC/C0/PTEN/C0 tumor cells resulted in compensatory upregulation of ERK signaling.

Conclusions: The studies show the utility of this GEM model of ovarian cancer for preclinical testing of novel PI3K/AKT/mTOR signaling inhibitors and provide evidence for compensatory signaling, suggesting that multiple rather than single agent targeted therapy will be more efficacious for treating ovarian cancers with activated PI3K/AKT/mTOR signaling. Clin Cancer Res; 17(23); 7359–72. ©2011 AACR.

Introduction

More than two-thirds of women diagnosed with ovarian carcinoma present with advanced stage disease, and their overall 5-year survival is only 28% (1, 2). Although the initial response of ovarian carcinomas to standard therapy (surgical debulking and chemotherapy with platinum-based drugs and taxanes) is often excellent, relapse with drug-resistant cancer usually occurs and patients succumb to their disease. Over the last several years, much progress has been made in identifying hallmark genetic lesions associated with each major subtype of ovarian carcinoma.

Novel therapeutics that target the signaling pathways dysregulated as a result of these molecular defects are being developed, with the hope that individualized therapeutic regimens based on the specific molecular defects present in a given patient’s tumor could be used alone or in combination with existing cytotoxic agents to improve clinical outcome.

Surgical pathologists continue to use morphology-based schemes for classifying ovarian carcinomas (OvCas) based largely on their degree of resemblance to nonneoplastic epithelia in the female genital tract. However, mounting clinico-pathologic and molecular data have led Kurman and Shih to propose a new model in which OvCas are divided into 2 main categories—type I and type II (3–5). Type I OvCas are suggested to be low grade, relatively indolent and genetically stable tumors that arise from well-defined precursor lesions such as endometriosis or so-called borderline tumors, and frequently harbor somatic mutations that dysregulate certain cell signaling pathways (e.g., KRAS, BRAF, CTNNB1, PTEN). Type I OvCas include most endometrioid, clear cell, and mucinous carcinomas and low-grade serous carcinomas. In contrast, type II OvCas are suggested to be high-grade, biologically aggressive tumors from their outset, with a propensity for metastasis.
Translational Relevance

Currently available therapies have improved survival for patients with advanced ovarian carcinoma, but many patients ultimately relapse and die from their cancer. There is great interest in designing new individualized therapeutic regimens based on the specific molecular defects present in a given patient’s tumor. Although many drugs and drug combinations are potentially available, identification of the most efficacious of these remains a challenging process that cannot easily be conducted in women with the disease. We have shown the preclinical utility of a genetically engineered mouse model of ovarian carcinoma that closely resembles human endometrioid ovarian cancers with Wnt and PI3K/Akt/mTOR pathway defects for comparison of the activities of multiple drugs targeting activated PI3K/Akt/mTOR signaling. The data suggest the mouse model strategy described here should help accelerate the transition of the most promising new therapies from the laboratory into clinical trials.

from small-volume primary lesions. Most type II OvCas are high-grade serous carcinomas, virtually all of which harbor mutant TP53 alleles (6). Genetic alterations that dysregulate the canonical Wnt (i.e., Wnt/β-catenin/β-catenin/Tcf) and PI3K/Akt/mTOR signaling pathways often occur together in human endometrioid adenocarcinoma (OEA; refs. 7, 8). Given substantial overlap in the molecular features (gene expression and mutational profiles) of tumors diagnosed as high-grade OEs, with high-grade serous carcinomas (7), some pathologists default the majority of gland-forming or near-solid cytologically high-grade carcinomas to the serous category, and consider true high-grade OEs to be rare or nonexistent (9). If only low-grade (prototypical type I) OEs are considered, the majority have mutations predicted to dysregulate canonical Wnt and/or PI3K/Akt/mTOR signaling and TP53 is usually wild type. Loss of function mutations in ARID1A (which encodes the AT-rich interactive domain-containing protein 1A) have also been recently reported in 30% of OEs (10). Given the frequency with which Wnt and PI3K/Akt/mTOR signaling is activated in OEs, drugs that target these pathways might prove to be particularly useful for treating patients with advanced-stage disease or in the adjuvant setting for patients with OEA who might be at risk of recurrence. Given our limited ability to exhaustively test multiple drug combinations, doses, and schedules in clinical trials, it is anticipated that animal models which closely mimic their human disease counterparts will provide an invaluable tool for the identification of multidrug regimens with greatest promise for efficacy in humans.

We previously described a murine model of (type I) OEA based on conditional inactivation of the Apc and Pten tumor suppressor genes following injection of adenovirus expressing Cre recombinase (AdCre) into the ovarian bursae of Apcflx/flx, Ptenflx/flx mice (7). Several characteristics of this mouse model suggest its relevance and tractability for testing novel therapeutic approaches. First, complicated breeding schemes are not needed to generate mice with the appropriate genotype once a breeding colony has been established. Second, tumors invariably arise within a few weeks following AdCre injection, and recapitulate the morphology and gene expression pattern of human OEs with comparable signaling pathway defects. Third, tumors arise in the ovary and in immunologically intact animals, so possible effects of the tumor microenvironment on therapeutic response can be assessed. Finally, similar to women with advanced ovarian cancer, 3 quarters of the mice develop hemorrhagic ascites, and nearly one quarter acquire overt peritoneal dissemination. To show this model’s utility for preclinical testing of novel therapeutics targeting the PI3K/Akt/mTOR signaling pathway, we pursued proof-of-principle studies showing the response of murine OEs to conventional chemotherapeutic drugs (cisplatin and paclitaxel) and mTOR and AKT inhibitors in vitro and in vivo. In addition, we show the application of a Cre-inducible luciferase reporter allele for longitudinal in vivo monitoring of tumor development and drug response in the mice.

Materials and Methods

Mouse strains and tumor induction

Apcflx/flx, Ptenflx/flx mice and ovarian bursal delivery of replication-incompetent recombinant AdCre have been described previously in detail (7). Briefly, Cre-mediated recombination in these animals results in a frameshift mutation at Apc codon 580 (11), and the deletion of exons 4 and 5 of Pten (12). For tumor induction, 5 × 10⁷ plaque-forming units of AdCre (purchased from the University of Michigan’s Vector Core) with 0.1% Evans Blue (Sigma-Aldrich Inc.) were injected into the right ovarian bursal cavities of 2- to 5-month-old female mice. In each mouse, the left ovarian bursa was not injected and served as control. Six weeks following AdCre injection, cohorts of mice were randomly assigned to drug treatment or vehicle control groups unless otherwise specified. Animals were euthanized by CO₂ asphyxiation following 3 to 4 weeks of drug treatment. All animal studies were done under a protocol approved by the University of Michigan’s University Committee on Use and Care of Animals.

Cell lines

W2671T and W2830T cell lines were generated from APC/PTEN−/− murine ovarian tumors. Briefly, fresh ovarian tumor tissues were mechanically minced with sterile scalpels and further digested at 37°C with 0.05% Trypsin-EDTA for 20 minutes. Cells were cultured for 5 passages in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% FBS/1% penicillin/streptomycin (P/S)/1% Insulin-transferrin-selenium (Invitrogen) in an incubator with 3% O₂/5% CO₂ (Model NAPCO 8000W, Thermal Scientific). Cells were maintained in DMEM supplemented with
PI3K/AKT/mTOR Inhibitors in an Ovarian Cancer Model

10% FBS/1% P/S in a standard 5% CO₂ incubator (Model 3307, Thermo Scientific). ID8 cells (spontaneously transformed ovarian surface epithelial cells from a C57BL/6 mouse) were obtained from KE Roby (University of Kansas Medical Center; ref. 13). The human OEA-derived cell line TOV-112D and ovarian carcinoma cell line A2780 were obtained from the American Type Culture Collection. TOV-112D cells harbor an activating (S37A) CTNNB1 mutation (14), but lack known PI3K/AKT/mTOR pathway defects. A2780 has biallelic inactivation of PTEN (9bp deletion in exon 5 and 37bp deletion in exon 8) but lacks known canonical Wnt pathway defects (15). To generate human ovarian carcinoma cells with dysregulation of both PI3K/AKT/mTOR and Wnt signaling, we transduced A2780 cells with a mutant (oncogenic) form of β-catenin (S33Y) by infecting cells with S33Y β-catenin–expressing retroviruses or control (PGS-CMV-CITE-neo; ref. 16).

**Drugs and treatment in mice**

Rapamycin (LC Laboratories) was reconstituted in 100% ethanol at 10 mg/mL, stored at −30°C and used in 5% Tween-80 and 5% PEG-400 before injection. Rapamycin was injected i.p. at concentrations of 4 mg/kg (n = 5) or 1 mg/kg (n = 8) in a final volume of 100 µL, 3 times weekly for 4 weeks. API-2 (Calbiochem) in 5% dimethyl sulfoxide (DMSO) was injected i.p. at a dose of 1 mg/kg in 100 µL daily for 3 to 4 weeks. Control mice were treated with 5% DMSO alone. Perifosine in 0.9% NaCl (Cayman Chemical) was given by oral gavage (125 mg/kg, twice weekly) for 4 weeks. The control group was administered 0.9% NaCl orally in parallel. Cisplatin (LC Laboratories) in 0.9% NaCl (5 mg/kg) and paclitaxel (LC Laboratories) in 5% DMSO (20 mg/kg) were administered i.p. injection, once a week for 4 weeks. Cisplatin and paclitaxel were administered on the same day, with paclitaxel being given 20 minutes after cisplatin. Control mice were given 0.9% NaCl first, then 5% DMSO.

**WST-1 cell proliferation assay**

WST-1 assays for cell proliferation were done per the manufacturer’s instructions (Roche Applied Science). Briefly, 1 × 10⁴ to 2 × 10⁴ cells were plated in each well of 96-well plates and cultured overnight. After addition of drugs, cells were incubated for another 24 hours. Cell proliferation reagent (10 µL per well) was then added and cells were incubated for another 2 to 3 hours. Absorbance of the samples at 450 and 600 nm was measured with a 96-well spectrophotometric plate reader (SpectraMax 190, Molecular Devices). Effects of drug treatments on cell proliferation were evaluated using 1-way ANOVA (GraphPad Prism, version 5.01 GraphPad Software, Inc.).

**Immunoblotting**

Cultured cells were treated with rapamycin (0.01–100 nmol/L) or API-2 (40 µmol/L) for up to 24 hours or with perifosine (40–80 µmol/L) for 2 hours. Whole cell protein lysates were then prepared in (radioimmunoprecipitation assay (RIPA) buffer containing Complete Protease Inhibitor Cocktail Tablets (Roche) and Phosphatase inhibitor cocktails (Sigma). Immunoblotting was done using standard protocols. Total protein lysates (30–50 µg) were separated on NuPage 4% to 12% Bis-Tris precast gels (Invitrogen) and then transferred to Immobilon-P membranes (Millipore). Antibody complexes were detected with enhanced chemiluminescent reagents (PerkinElmer) and exposed to HyBlot CL film (Denville Scientific Ic.).

**Histopathology and immunohistochemistry**

After drug treatment, all mice were euthanized and examined at necropsy for gross organ abnormalities. The genital tract and other major organs were collected, fixed in 10% (v/v) buffered formalin, embedded in paraffin, and processed for staining with hematoxylin and eosin (H&E). Histopathologic evaluation of tumor and other tissues was done by a surgical pathologist with expertise in gynecologic cancer diagnosis (K.R. Cho). Immunohistochemical (IHC) staining was done on formalin-fixed, paraffin-embedded tissues or frozen sections using standard methods. For mouse primary antibodies, mouse on mouse kit (M.O.M., Vector Laboratories Inc.) was used to reduce nonspecific staining per the manufacturer’s instructions. Immunofluorescence staining was carried out as previously described (14). Briefly, cells were grown in chamber slides for 2 days, then fixed with 4% paraformaldehyde for 20 minutes and permeabilized with 1% goat serum/0.5% Triton X-100/PBS for 15 minutes at room temperature. After washing with PBS, slides were blocked with 2% goat serum/0.2% TritonX-100/PBS for 60 minutes. Cells were incubated with primary antibody at 4°C overnight. After washing with PBS, cells were incubated with Alexa 594 Red-conjugated secondary antibody at a dilution of 1:1,000 for 60 minutes at room temperature. Slides were washed with PBS and then counterstained with Hoechst (1:1,000) for 5 minutes. Prolong Gold antifade reagent (Fisher) was used to mount the coverslips.

**Antibodies**

The following primary antibodies were used for IHC or immunofluorescent staining: Mouse anti–β-catenin (Transduction Laboratories); Mouse anti–α-inhibin (Serotec Ltd.); Rat anti-cytokeratin 8 (CK8, tROMA 1, Developmental Studies Hybridoma Bank, University of Iowa); Rat anti-Ki67 (clone TEC-3, Dako); Rabbit anti-pten (clone 138G6, Cell Signaling, #9559); Rabbit anti-cleaved caspase-3 (Asp175) Cell Signaling, #9661); Rabbit anti-phospho-S6 Ribosomal Protein (Ser235/236; Cell Signaling, #8587); and mouse anti-CD10 (Novocasta, nC1L-CD270). Antibodies used for immunoblotting were: Rabbit anti-phospho-AKT (Ser473; Cell Signaling, #4060); Rabbit anti-AKT (Cell Signaling, #9272); Mouse anti-phospho-ERK (E-4; Santa Cruz, #7383); Rabbit anti-ERK1/2 (Cell Signaling, #9102); Rabbit anti-phospho-S6 Ribosomal Protein (Ser235/236; Cell Signaling, #8587); Mouse anti-S6 Ribosomal Protein (Cell Signaling, #2317); Rabbit anti-phospho-p70 S6 (Thr389) kinase (Cell Signaling, #9205); Rabbit anti-p70 S6 kinase (Santa Cruz, #S-
In vivo bioluminescence imaging

The mouse luciferase reporter strain Rosa26L-S-Luc/+ (17) was purchased from the Jackson Laboratory (stock #005125). Luciferase expression in the mouse ovarian surface epithelium was induced by ovarian intrabursal injection of AdCre. Mice were imaged using an IVIS Image System 200 Series (Xenogen Corporation). During the imaging procedure, mice were anaesthetized with a constant flow of 1.5% isoflurane from the IVIS manifold and then administered a single i.p. dose of α-luciferin (150 mg/kg, Biosynth International, Inc.) in a volume of 100 μL in normal saline. Image acquisition was initiated approximately 10 minutes after injection of α-luciferin. The bioluminescence signals (photons/s) emitted from the surface epithelium was induced by ovarian intrabursal injection of AdCre. Mice were imaged using an IVIS Image System 200 Series (Xenogen Corporation). For studies of tumor-bearing mice were collected using sequential mode until reaching the earliest time point at which OEAs or precursor lesions could be detected. Cohorts of 43 Apcfl/fl;Ptenfl/fl;Rosa26L-S-L-Luc/+ mice were crossed to generate Apcfl/fl;Ptenfl/fl;Rosa26L-S-L-Luc/+ mice. After baseline imaging 6 weeks after AdCre infection, mice were treated with either drug or vehicle. Treated mice were then reimaged at weekly intervals for 4 weeks. For each animal, bioluminescence was normalized to its baseline (before treatment, 0 week) and signals were adjusted to the same color scale for the entire time course.

Results

Temporal analysis of ovarian murine tumor development following AdCre injection

Our previous studies have shown that mice-bearing APC−/−/PTEN−/− tumors survive 11 to 12 weeks on average (range 7–19 weeks) after injection of AdCre. To assess the possible value of this model for studying effects of chemotherapy or early intervention, we sought to define the earliest time point at which OEAs or precursor lesions could be detected. Cohorts of Apcfl/fl;Ptenfl/fl;Rosa26L-S-L-Luc/+ mice (total, n = 43) were evaluated weekly from 1 to 6 weeks after ovarian bursal AdCre injection. Mice were euthanized and their genital tracts evaluated for gross and microscopic lesions; data are summarized in Table 1. No gross or microscopic lesions were detectable in any of the mice examined at 1 (n = 2) or 2 (n = 8) weeks after AdCre injection. In 6 of 10 mice euthanized after 3 weeks, microscopic dysplastic lesions were found exclusively in the injected (right) ovaries (Fig. 1A and B). Multifocal aggregates of epithelial cells (tumorlets), morphologically indistinguishable from those seen in well-established tumors, were present on the ovarian surface. On the basis of IHC staining, cells in the surface tumorlets were cytokeratin 8-positive (Fig. 1C) and α-inhibin-negative (Fig. 1D), consistent with epithelial differentiation. As expected, the tumor cells also showed strong nuclear expression of β-catenin (Fig. 1E) and absence of PTEN expression (Fig. 1F). In 13 mice euthanized 6 weeks post-AdCre injection, 2 had microscopic ovarian tumorlets and 11 had grossly visible, small ovarian tumors (Fig. 1G); none had developed ascites or peritoneal metastasis. Macroscopically, the 6-week tumors showed areas of overt glandular differentiation (Figs. 1H and 1I) admixed with more poorly differentiated and spindle cell areas as observed in the more advanced tumors we described previously (7).

Development of APC−/−/PTEN−/− murine ovarian tumors is not preceded by endometriosis

A substantial proportion of human ovarian carcinomas with endometrioid or clear cell differentiation are believed to arise from endometriosis (18). Notably, we did not observe endometriosis-like lesions in any of the 43 Apcfl/fl;Ptenfl/fl;Rosa26L-S-L-Luc/+ mice evaluated 1 to 6 weeks following AdCre injection or, in our previous study, in mice with well-established APC−/−/PTEN−/− tumors (7). After ovarian bursal injection of AdCre, groups of mice where only the Apc (Apcfl/fl) or Pten (Ptenfl/fl) genes were individually inactivated were monitored for 12 to 13 months for tumor development. No ovarian epithelial tumors were found in either group, though benign endometrioid-type glands and stroma morphologically similar to endometriosis were observed at the end of the monitoring period in the injected (right) ovaries in 9 of 49 Apcfl/fl;Ptenfl/fl mice. Similar lesions were identified in the un.injected (left) ovaries of 6 mice (Fig. 2A and B). In Ptenfl/fl control mice (n = 47), endometriosis was observed in one AdCre injected ovary. We did not observe tumor formation or endometriosis lesions in any of the 24 C57BL/6J mice monitored from 3 to 13 months following ovarian bursal AdCre injection. As expected for endometriosis, IHC staining showed strong CK8 positivity in the glandular epithelium and scattered CD10-positive cells in the adjacent endometriotic stroma (Fig. 2C and D). Expression of α-inhibin was weak in the stroma relative to the granulosa cells in the ovarian follicles (Fig. 2E). Importantly, the glandular epithelium showed exclusively membranous staining for β-catenin, indicating absence of Cre-mediated inactivation of

### Table 1. Ovarian tumor development following AdCre injection

<table>
<thead>
<tr>
<th>Week</th>
<th>Number of mice</th>
<th>Microscopic tumor</th>
<th>Macroscopic tumor</th>
<th>% with tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>10</td>
<td>6</td>
<td>0</td>
<td>60</td>
</tr>
<tr>
<td>4</td>
<td>7</td>
<td>6</td>
<td>0</td>
<td>85.7</td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>6</td>
<td>13</td>
<td>2</td>
<td>11</td>
<td>100</td>
</tr>
</tbody>
</table>
Apc, even in the AdCre-injected ovaries (Fig. 2F). This finding, in addition to our observation of endometriosis-like lesions in the uninjected and injected ovaries, suggests, but does not definitively prove, that the development of endometriosis in a subset of the mice is not dependent on Cre-mediated inactivation of Apc or Pten, but may instead reflect a background rate of endometriosis development that varies to some degree with the genetic background of the mice studied.

**Status of PI3K/AKT/mTOR signaling in murine ovarian cancer cells determines response to AKT and mTOR inhibitors, but not to conventional cytotoxic drugs**

The PI3K/AKT/mTOR signaling pathway plays an important role in the regulation of cell growth, proliferation, and survival by controlling the phosphorylation of several translation factors. We first wished to test effects of selected PI3K/AKT/mTOR pathway-targeted therapies and conventional cytotoxic agents on murine tumor cell...
proliferation in vitro. WST-1 proliferation assays were done using 3 transformed murine ovarian surface epithelial cell lines. The W2671T and W2830T cell lines were established in our laboratory following primary culture of murine OEs induced by AdCre injection in Apcfl/fl; Ptenfl/fl mice. These cells show epithelial-like cobblestone morphology in culture (Supplementary Fig. S1A and B). The cells are cytokeratin-8- (Supplementary Fig. S1C) and E-cadherin-positive, and vimentin-negative (Supplementary Fig. S1D) based on immunofluorescent staining. ID8 cells, a spontaneously transformed mouse ovarian surface epithelial cell line lacking known PI3K/AKT/mTOR and canonical WNT pathway defects, were also used for our studies (13). Cells were incubated with different doses of drugs for 24 hours, and data were normalized to vehicle treatment. W2671T cells displayed profound dose-dependent growth inhibition in response to rapamycin, cisplatin, and paclitaxel (Fig. 3A–C). More modest inhibitory effects were observed with perifosine, a synthetic alkyl phospho-lipid that targets cell membranes and inhibits PKB-mediated AKT activation (Fig. 3D; ref. 19). Statistically significant growth inhibition was observed in W2671T at the highest (40 μmol/L) perifosine concentration. In contrast, ID8 cells were sensitive to cisplatin and paclitaxel but showed minimal response to rapamycin, and no response to perifosine, even at the highest concentrations. These results confirm differential sensitivity to drugs that target PI3K/AKT/mTOR signaling in murine ovarian cancer cells, depending on the presence or absence of PI3K/AKT/mTOR pathway defects in the cells.

Characterization of PI3K/AKT/mTOR signaling pathway regulation in murine and human ovarian cancer cells after rapamycin treatment in vitro

The serine/threonine protein kinase mTOR exists in 2 functional complexes, mTORC1 and mTORC2. mTORC1 is a major regulator of cell growth, containing mTOR, raptor, and mLST8. mTORC1 phosphorylates ribosomal protein S6 kinase beta-1 (S6K1) at Thr389, which is necessary for
activation and phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1). Phosphorylation of 4E-BP1 blocks its binding to eIF4E and results in increased translation of capped mRNAs. Phosphorylated S6K1 further phosphorylates ribosomal protein S6 (S6) to promote ribosome biogenesis. Rapamycin suppresses both cell proliferation and cell growth through inhibition of mTORC1 (20, 21). mTORC2, comprised of...
mTOR, Rictor, mSin1, and mLST8, is relatively resistant to rapamycin. mTORC2 regulates activation of Akt, and mTORC2 activity is stimulated by growth factors such as insulin and insulin growth factor-1 (IGF-1).

To further characterize the time and dose-dependent downstream effects of drug-target interactions in vitro, the status of several PI3K/AKT/mTOR signaling pathway components was evaluated in 2 murine OEA-derived cell lines (W2671T, W2830T) before and after rapamycin treatment. As expected, in the absence of drug treatment, W2671T and W2830T cells exhibited constitutive phosphorylation (p) of AKT (Ser473), S6K1 (Thr389), and S6 (Ser235/236). In contrast, there was no or very low level expression of pAKT, pS6K1, and pS6 in ID8 cells, which lack known PI3K/AKT/mTOR and Wnt signaling pathway defects (Fig. 4A). Levels of p4E-BP1 were similarly low in all 3 cell lines. Several investigators have reported that 100 to 1,000 nmol/L rapamycin treatment can inhibit activation of endogenous mTOR (22, 23). Treatment of W2671T and W2830T cells with 100 nmol/L rapamycin more than a 24-hour time course showed complete loss of pS6K1 by the 0.5 hours time point and loss of pS6 between 0.5 and 4 hours. The timing of pAKT loss in response to rapamycin varied between the 2 lines, but pAKT was undetectable in both lines by the 24 hours time point (Fig. 4B). Levels of p4E-BP1 were largely unchanged by rapamycin treatment, in keeping with recent reports that combined inhibition of Akt and Erk signaling is required to suppress 4E-BP1 phosphorylation (24). To determine the minimal concentration of rapamycin needed to abolish pS6K1 and pS6 expression in our murine APC^-/PTEN^- OEA cells, W2671T cells were treated for 2 hours with doses of rapamycin ranging from 0.01 to 100 nmol/L. Expression of pS6K1 and pS6 was virtually undetectable with rapamycin concentrations as

![Figure 4](image-url)
low as 0.1 nmol/L (Fig. 4C). In contrast to W2671T cells treated with 100 nmol/L rapamycin (Fig. 4B), cells treated with 1 nmol/L of rapamycin showed no change in AKT phosphorylation more than a 24-hour time course (Fig. 4D). At both the 1 nmol/L and 100 nmol/L rapamycin doses, early and sustained decreases in phosphorylation of both S6K1 and S6 were observed (Fig. 4B and D). These findings suggest that, in our model system, low doses of rapamycin inhibit only mTORC1, while higher doses are able to inhibit both mTORC1 and mTORC2. Interestingly, p4E-BP1 (Thr70) was elevated after 2 hours of low-dose (1 nmol/L) rapamycin treatment, peaked at 4 hours, then gradually decreased and was completely inhibited at 24 hours (Fig. 4D). p4E-BP1 (Thr37/46), the form with phosphorylation of the priming sites required for Thr70 phosphorylation, was increased between 0.5 and 16 hours and was nearly undetectable at 24 hours (Fig. 4D). These changes in p4E-BP1 levels were not observed with the high dose (100 nmol/L) of rapamycin (Fig. 4B).

We wished to determine whether rapamycin treatment yielded comparable effects in human ovarian cancer cells with canonical Wnt and/or PI3K/Akt/mTOR pathway defects. The TOV-112D cell line was derived from a human OEA and harbors mutant CTNNB1 and wild-type PTEN alleles (14). As expected, TOV-112D cells expressed substantial levels of transcriptionally active β-catenin (dephosphorylated on Ser37 or Thr41) that were not affected by rapamycin. pAkt was undetectable at baseline and after 2 hours of treatment with rapamycin doses between 0.1 and 100 nmol/L (Supplementary Fig. S2A), and remained undetectable after 24 hours of treatment (data not shown). Expression of pS6K1 and pS6 was inhibited by treatment with rapamycin concentrations as low as 0.1 to 1.0 nmol/L. p(Ser9)GSK3β was modestly inhibited by 1 to 100 nmol/L rapamycin, consistent with GSK3β as a downstream target of Akt in cells with intact PI3K/Akt/mTOR signaling. A2780 ovarian carcinoma cells have biallelic inactivation of PTEN (15). These cells were transduced with a mutant (S33Y) form of β-catenin to generate a human ovarian cancer cell line with dysregulation of both Wnt and PI3K/Akt/mTOR signaling. As expected, and in contrast to TOV-112D cells, A2780 cells with and without mutant β-catenin show elevated pAkt at baseline (Supplementary Fig. S2B). Effects of rapamycin on PI3K/Akt/mTOR pathway components were largely similar in the presence and absence of mutant β-catenin, indicating Wnt pathway defects do not significantly alter effects of rapamycin in ovarian cancer cells with dysregulated PI3K/Akt/mTOR signaling. Our data are also consistent with previous reports that phosphorylation of S6K and S6 is not regulated by β-catenin (25).

**Growth of APC−/PTEN− murine OEs is inhibited in vivo by conventional chemotherapy and drugs targeting activated PI3K/AKT/mTOR signaling**

The response of mouse OEs to AKT and/or mTOR inhibitors in vivo would help show the model’s potential utility for testing novel drugs targeting activated PI3K/AKT/mTOR signaling. Because clinical trials in ovarian cancer patients would likely compare the activity of targeted agents to that of conventional cytotoxic chemotherapy, it would also be useful to know whether the murine APC−/PTEN− tumors respond to cisplatin/paclitaxel in vivo. We therefore tested tumor-bearing mice for response to rapamycin, a first-generation mTOR inhibitor that directly binds mTORC1, a downstream effector of activated AKT. Tumor response to conventional combination therapy with cisplatin and paclitaxel and 2 mechanistically distinct AKT inhibitors (API-2 and perifosine) was also evaluated. API-2 (Akt/protein kinase B signaling inhibitor-2), also known as triciribine, is a cell-permeable tricyclic nucleoside that selectively inhibits the cellular phosphorylation/activation of AKT (26), while perifosine targets cell membranes and inhibits PKB-mediated AKT activation (19). Perifosine has also been shown to facilitate degradation of mTOR signaling pathway components including mTOR, raptor, rictor, S6K, and 4E-BP1 (27).

For these experiments, AdCre was injected into the right ovarian bursa of Apc<sub>fl<sup>lox</sup>/fl<sup>lox</sup></sub>Pten<sub>fl<sup>lox</sup>/fl<sup>lox</sup></sub> mice and drug (or vehicle) treatment was initiated after 6 weeks, when all of the mice were expected to have developed at least small tumors based on the studies described above. Data collected after 4 weeks of treatment with rapamycin (2 doses), API-2, perifosine and cisplatin/paclitaxel are shown in Fig. 5A–D, respectively. Treatment with each regimen, including both low (1 mg/kg) and high (4 mg/kg) doses of rapamycin, resulted in statistically significant inhibition of tumor growth more than 4 weeks based on measurements of tumor volume at necropsy. Microscopic analysis of H&E stained sections showed that residual drug-treated tumors were morphologically similar to vehicle-treated tumors (data not shown). None of the drug-treated animals developed liver metastases during the treatment period (compared with 3 of the vehicle-treated mice), and only 2 of 36 (6%) drug-treated mice (both in the low-dose rapamycin group) developed ascites, compared with 12 of 33 (36%) vehicle-treated mice. These data are summarized in Table 2.

Effects of drug treatment on cell proliferation in the residual ovarian tumors were evaluated by IHC staining for Ki-67 in tumor tissue sections. The Ki-67 index was defined as the percentage of Ki-67 positive cells in the most cellular areas of tumor. Data from two 400× fields were collected and averaged. The Ki-67 index was significantly reduced in rapamycin-treated tumors (n = 12) compared with vehicle-treated tumors (n = 6) in control mice (28.03 ± 3.27% vs. 41.84 ± 4.82%, P = 0.0418). The Ki-67 index was also lower in perifosine-treated tumors relative to vehicle-treated controls, but the difference did not achieve statistical significance (31.49 ± 1.61% vs. 46.15 ± 6.61%, P = 0.097). API-2 had no appreciable effect on the Ki-67 index (48.80 ± 5.41% vs. 42.21 ± 4.47%, P = 0.3747).

Apoptosis in rapamycin versus vehicle-treated tumors was evaluated by IHC staining for the active form of caspase-3, cleaved caspase-3 (CC3), using an antibody that recognizes the p20/p17 subunit in the cytoplasm of apoptotic cells. Only rare positive cells were identified in tissue...
sections from tumors treated with rapamycin or vehicle (data not shown), and no significant difference was noted between the 2 groups. This finding is consistent with previous reports that rapamycin and its analogues can sensitize tumor cells in culture to cisplatin-induced apoptosis, but have minimal effects on apoptosis when used alone (28).

Effects of cisplatin and paclitaxel on tumor cell proliferation and apoptosis could not be analyzed because residual tumor was identified in only 1 of 6 treated animals. Immunoblotting and IHC staining were used to analyze residual APC<sup>−/PTEN<sup>−</sup> tumors remaining after 4 weeks of treatment with rapamycin. Only small amounts of tumor tissue remained after treatment, limiting the number of studies that could be done. We found that pS6 (Ser235/236) levels were lower, and pAKT levels slightly increased, in rapamycin-treated tumors compared with those receiving vehicle (Supplementary Fig. S3, top panel). IHC staining of residual tumor tissue confirmed significant reduction of pS6 in the rapamycin-treated tumors compared with controls (Supplementary Fig. S3, bottom panels).

Figure 5. Inhibition of APC<sup>−/PTEN<sup>−</sup> murine ovarian tumor growth in vivo by conventional chemotherapy and drugs targeting activated PI3K/Akt/mTOR signaling. Small ovarian tumors present 6 weeks after AdCre injection were treated for 4 weeks with vehicle or rapamycin (1 mg/kg and 4 mg/kg; A), API-2 (B), perifosine (C), or cisplatin plus paclitaxel (D). Mice were euthanized at the end of the treatment period and right ovarian tumor volume was measured (length × width × height) using calipers. All treated groups showed significantly smaller tumors than controls. P values from 2-sample t tests on tumor volume are shown. E, bioluminescence imaging was done weekly in tumor-bearing animals treated with vehicle or rapamycin. Treatment was initiated 6 weeks after AdCre injection of the right ovarian bursae of Apc<sup>fl/fl</sup>/Pten<sup>fl/fl</sup>/Rosa26<sup>L-S-L-luc/+</sup> mice. Representative images before and after 4 weeks of treatment with rapamycin or vehicle are shown. Bioluminescence is indicated as photons/second/cm<sup>2</sup>. Red signals correspond to maximal intensity, violet to minimal intensity, and other colors representing values in between. F, graph showing fold-change in luciferase activity based on BLI imaging of vehicle versus rapamycin-treated animals over the 4-week treatment course. G, comparison of tumor volume and BLI signal at study endpoint in vehicle and rapamycin-treated animals.
**Tumor imaging**

The ability to noninvasively and quantitatively image localized and metastatic OEs in live animals would permit repeated and accurate measurements of tumor burden, increasing statistical power and reducing the number of animals needed to test each therapeutic regimen. To show the feasibility of this approach, we further engineered our OEA model to include a luciferase reporter allele that can be activated by AdCre. Mice with a Cre-activatable form of firefly luciferase allele present at the ubiquitously expressed Rosa26 locus were crossed with Apc\textsuperscript{lox/lox}; Pten\textsuperscript{lox/lox} mice and bioluminescence in the rapamycin-treated mice increased only minimally in 1 mouse (Rap1) and decreased in the other mouse (Rap2). Comparison of tumor volume and BLI signal at the study endpoint is shown in Fig. 5G.

**Discussion**

Thus far, clinical trials of new drugs have relied heavily on preclinical studies testing drug effects on OvCa-derived cell lines in culture or xenografted into immune-compromised mice. These systems have a number of shortcomings, reviewed by Frese and Tuveson among others (33), and there is hope that genetically engineered mouse (GEM) models of OvCa will prove superior to cultured cells and tumor xenografts for testing the efficacy of novel therapeutic regimens. Existing GEM models of OvCa have been surprisingly underutilized for this purpose. In the studies presented here, we have focused on addressing the utility of a robust mouse OEA model, based on conditional inactivation of the Apc and Pten tumor suppressor genes in the ovarian surface epithelium, for preclinical testing of agents targeting activated PI3K/AKT/mTOR signaling.

Although many OEs are low stage at diagnosis and have an excellent prognosis, a substantial fraction of OEs present at FIGO stage III or IV. On the basis of a series of cases from which data were prospectively collected more than a 20-year period at a single center, 48% were high stage at diagnosis and these were associated with poor (less than 12%) 5-year progression-free survival after platinum-based therapy (34). It is reasonable to hope that drugs that target activated PI3K/Akt/mTOR signaling might prove to be useful for treating patients whose tumors harbor mutations that dysregulate this signaling pathway, particularly those with high stage disease or risk of recurrence. Given the modest number of patients with OEs and the many drug combinations, doses, and schedules that could be explored in clinical trials, we hypothesized that our mouse OEA model might prove valuable for validating the concept of targeting PI3K/AKT/mTOR signaling in OEs and in defining a limited number of higher priority agents and combinations. We report data here showing that agents targeting PI3K/AKT/mTOR signaling are active in vitro and in vivo against OEs, and that longitudinal imaging approaches with luciferase-based reporters to measure tumor burden and dissemination might be particularly promising.

Platinum-taxane combination chemotherapy is well established as first-line therapy for advanced ovarian cancer, including OEs (35). Initial response rates exceed 80%, but most patients relapse and response of recurrent disease to other agents such as doxorubicin, gemcitabine, topotecan,
and etoposide is unpredictable. Moreover, the likelihood of response decreases with each subsequent relapse. Attempts to overcome chemoresistance following platinum/taxane therapy using different classes of chemotherapeutic agents in various combinations, doses, and schedules have led to only incremental improvements in overall survival. More recently, improved understanding of ovarian cancer biology and molecular genetics has led to the development of targeted therapies, several of which have been tested in clinical trials. These include agents that target angiogenesis, Erbb family members such as epidermal growth factor receptor and ERBB2, and α-FR (reviewed by Yap and colleagues; ref. 35). Although the PI3K/Akt/mTOR signaling pathway is frequently activated in human ovarian cancers, including OEs as discussed above, clinical trials assessing the potential of PI3K, Akt, or mTOR inhibitors for treating ovarian cancer have been somewhat limited thus far. In a small (15 subject) phase I study of weekly temsirolimus
PI3K/AKT/mTOR Inhibitors in an Ovarian Cancer Model

(mTOR inhibitor also known as CCI-779) and topotecan for treatment of advanced or recurrent gynecologic malignancies—nearly half of which were ovarian cancers—there were no complete or partial responses. Furthermore, myelosuppression was found to be dose limiting for the combination, and patients who had received prior pelvic radiation were unable to tolerate the treatment (36). A phase II trial assessing temsirolimus as a single agent in patients with persistent or recurrent ovarian cancer showed modest effects, but progression-free survival was below the level that would warrant phase III studies in unselected patients (37). Interestingly, a phase II study of another mTOR inhibitor, everolimus, has shown encouraging results as a single agent for patients with recurrent endometrioid adenocarcinomas of the endometrium (38), which like OEAs, have frequent mutations that dysregulate PI3K/Akt/mTOR signaling. Our data, using both in vitro and in vivo model systems, suggest that Akt and mTOR inhibitors are likely to have efficacy for treating ovarian cancers with PI3K/Akt/mTOR pathway defects. Santikuvong and colleagues recently showed that dual targeting of PI3K and mTOR inhibited growth of ovarian carcinomas arising in another murine GEM model based on conditional activation of a mutant K-ras allele and biallelic inactivation of Pten (39). Collectively, our data provide support for using GEM models of ovarian cancer to help preselect drug regimens with greatest promise for efficacy in human clinical trials. For example, such models could be used to help determine whether a given targeted agent is likely to be more effective given simultaneously with, or after conventional therapy. Toxicities likely to be dose limiting could also be identified.

A number of different modalities have been used to noninvasively image tumors in living animals, including those developing in the context of GEM models. These modalities include high resolution ultrasound (40), micro-computed tomography (micro-CT; ref. 41), micro-position emission tomography (micro-PET; ref. 42), MRI (43), and BLI (44, 45). Although each modality has pros and cons, some of the advantages of BLI include its high sensitivity, relatively low cost, short image acquisition times and relative ease of use with minimal image postprocessing requirements (44). Our model system has been engineered such that the luciferase reporter is synchronously activated when Pten and Apc are inactivated, allowing tumors to be monitored longitudinally over time with BLI, essentially from their inception. We have also shown that BLI can be effectively used to monitor effects of therapy.

The PI3K/mTOR and MEK/ERK signaling pathways likely cooperate in many tumor types to drive tumor growth, promote tumor cell survival and mediate resistance to therapy. Simultaneous inhibition of both pathways with targeted agents has been shown to substantially enhance antitumor effects in vitro and in vivo (31, 32, 46). Similar to our findings in OEA-derived cell lines, Rahmani and colleagues showed that treatment of leukemia cells with perifosine, which inhibits PI3K/Akt/mTOR signaling upstream of mTORC1, also induced Erk activation (47). Notably, combined treatment with the Mek inhibitor PD184352 and perifosine strikingly induced apoptosis in multiple malignant human hematopoietic cells. Although effects of Akt and mTOR inhibition on Erk activation may vary with cell type and context, our data suggest that clinical trials involving the use of targeted agents for ovarian cancers with activated PI3K/Akt/mTOR signaling should focus not only on improving the activity of conventional cytotoxic drugs by combining them with targeted agents, but also on designing rational combinations of targeted agents that inhibit complementary or compensatory cell survival pathways. We anticipate that animal models such as the one described here should facilitate identification of the most successful combination therapies for subsequent evaluation in clinical trials.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This work was supported by grants from the National Cancer Institute (RO1 CA4172) and the Department of Defense Ovarian Cancer Research Program (W81XWH-08-1-0453).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 31, 2011; revised August 24, 2011; accepted August 30, 2011; published OnlineFirst September 8, 2011.

References

Wu et al.

Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma

Rong Wu, Tom C. Hu, Alnawaz Rehemtulla, et al.

 Clin Cancer Res 2011;17:7359-7372. Published OnlineFirst September 8, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-11-1388

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2011/09/09/1078-0432.CCR-11-1388.DC1

Cited articles
This article cites 45 articles, 10 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/17/23/7359.full.html#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
/content/17/23/7359.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.